GlassScriptPhysician profile
John C Huang
NPI 1306860432
$36,398.95
in general payments reported to CMS, 2019-2025
24 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $333 · 2021: $458 · 2022: $1,007 · 2023: $285 · 2024: $395 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32,913.46 | 2019 | |
| Abbvie INC. | $900.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.04 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $277.75 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $249.42 | 2024-2025 | Rexulti, Nuedexta |
| Coherus Oncology, INC. | $216.79 | 2023 | |
| Lilly USA, LLC | $200.99 | 2019 | |
| Amgen INC. | $199.99 | 2019-2021 | |
| Eisai INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $123.19 | 2021 | |
| Daiichi Sankyo INC. | $119.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $116.53 | 2020 | |
| Ocular Therapeutix, INC. | $94.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.61 | 2019 | |
| Allergan, INC. | $88.62 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $70.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.92 | 2023 | |
| Alimera Sciences, INC. | $45.82 | 2019 | |
| Astellas Pharma US INC | $45.76 | 2024 | Izervay |
| Novo Nordisk INC | $34.38 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $30.12 | 2024 | Syfovre |
| Sunovion Pharmaceuticals INC. | $17.97 | 2022 | |
| Biogen, INC. | $17.90 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.